Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence
In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2017-05, Vol.69 (19), p.2468-2469 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2469 |
|---|---|
| container_issue | 19 |
| container_start_page | 2468 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 69 |
| creator | Khan, Abdur Rahman Riaz, Haris Farid, Talha Bolli, Roberto |
| description | In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level |
| doi_str_mv | 10.1016/j.jacc.2017.02.063 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899106072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109717361235</els_id><sourcerecordid>1899106072</sourcerecordid><originalsourceid>FETCH-LOGICAL-e207t-e32bd917cff74eb0118c9a7841c165fd3ed362babef0aa62fb2b73f13817ef483</originalsourceid><addsrcrecordid>eNpd0U1v1DAQBmALgehS-AMcUCQuXBJm7CS2EZdqVWhFW6oC4mjFzpg67MbFTlbi35Oo5dLTXB7N18vYa4QKAdv3QzV0zlUcUFbAK2jFE7bBplGlaLR8yjYgRVMiaHnEXuQ8AECrUD9nR1zVutZKbtjZFc0puvhrDFM4UHET8u_iZ5hui-vtty-6OB9vgw1TTPlDcUXUFz6m4jKmRUY756k4PYSeRkcv2TPf7TK9eqjH7Men0-_bs_Li6-fz7clFSRzkVJLgttconfeyJguIyulOqhodto3vBfWi5baz5KHrWu4tt1J4FAol-VqJY_buvu9din9mypPZh-xot-tGinM2qLRGaEHyhb59RIc4p3HZblUKJCxjF_XmQc12T725S2Hfpb_m_48W8PEe0HLWIVAy2YX15D4kcpPpYzAIZo3EDGaNxKyRGOBmiUT8A3b8fJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1898070841</pqid></control><display><type>article</type><title>Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence</title><source>Elsevier ScienceDirect Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Khan, Abdur Rahman ; Riaz, Haris ; Farid, Talha ; Bolli, Roberto</creator><creatorcontrib>Khan, Abdur Rahman ; Riaz, Haris ; Farid, Talha ; Bolli, Roberto</creatorcontrib><description>In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level <25 mg/dl with the median duration of low LDL level being ~43 weeks.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2017.02.063</identifier><identifier>PMID: 28494987</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiology ; Cardiovascular diseases ; Cholesterol ; Clinical trials ; Cognition ; Cognitive ability ; Health risks ; Heart ; Hypercholesterolemia ; Incidence ; Inhibitor drugs ; Kexin ; Lipids ; Low density lipoprotein ; Patients ; Populations ; Protease ; Protease inhibitors ; Proteinase ; Proteinase inhibitors ; Risk ; Serine ; Side effects ; Subtilisin ; Therapy</subject><ispartof>Journal of the American College of Cardiology, 2017-05, Vol.69 (19), p.2468-2469</ispartof><rights>2017 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited May 16, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0735109717361235$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28494987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Abdur Rahman</creatorcontrib><creatorcontrib>Riaz, Haris</creatorcontrib><creatorcontrib>Farid, Talha</creatorcontrib><creatorcontrib>Bolli, Roberto</creatorcontrib><title>Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level <25 mg/dl with the median duration of low LDL level being ~43 weeks.</description><subject>Cardiology</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Health risks</subject><subject>Heart</subject><subject>Hypercholesterolemia</subject><subject>Incidence</subject><subject>Inhibitor drugs</subject><subject>Kexin</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Patients</subject><subject>Populations</subject><subject>Protease</subject><subject>Protease inhibitors</subject><subject>Proteinase</subject><subject>Proteinase inhibitors</subject><subject>Risk</subject><subject>Serine</subject><subject>Side effects</subject><subject>Subtilisin</subject><subject>Therapy</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpd0U1v1DAQBmALgehS-AMcUCQuXBJm7CS2EZdqVWhFW6oC4mjFzpg67MbFTlbi35Oo5dLTXB7N18vYa4QKAdv3QzV0zlUcUFbAK2jFE7bBplGlaLR8yjYgRVMiaHnEXuQ8AECrUD9nR1zVutZKbtjZFc0puvhrDFM4UHET8u_iZ5hui-vtty-6OB9vgw1TTPlDcUXUFz6m4jKmRUY756k4PYSeRkcv2TPf7TK9eqjH7Men0-_bs_Li6-fz7clFSRzkVJLgttconfeyJguIyulOqhodto3vBfWi5baz5KHrWu4tt1J4FAol-VqJY_buvu9din9mypPZh-xot-tGinM2qLRGaEHyhb59RIc4p3HZblUKJCxjF_XmQc12T725S2Hfpb_m_48W8PEe0HLWIVAy2YX15D4kcpPpYzAIZo3EDGaNxKyRGOBmiUT8A3b8fJA</recordid><startdate>20170516</startdate><enddate>20170516</enddate><creator>Khan, Abdur Rahman</creator><creator>Riaz, Haris</creator><creator>Farid, Talha</creator><creator>Bolli, Roberto</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170516</creationdate><title>Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence</title><author>Khan, Abdur Rahman ; Riaz, Haris ; Farid, Talha ; Bolli, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e207t-e32bd917cff74eb0118c9a7841c165fd3ed362babef0aa62fb2b73f13817ef483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cardiology</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Health risks</topic><topic>Heart</topic><topic>Hypercholesterolemia</topic><topic>Incidence</topic><topic>Inhibitor drugs</topic><topic>Kexin</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Patients</topic><topic>Populations</topic><topic>Protease</topic><topic>Protease inhibitors</topic><topic>Proteinase</topic><topic>Proteinase inhibitors</topic><topic>Risk</topic><topic>Serine</topic><topic>Side effects</topic><topic>Subtilisin</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Abdur Rahman</creatorcontrib><creatorcontrib>Riaz, Haris</creatorcontrib><creatorcontrib>Farid, Talha</creatorcontrib><creatorcontrib>Bolli, Roberto</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Abdur Rahman</au><au>Riaz, Haris</au><au>Farid, Talha</au><au>Bolli, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2017-05-16</date><risdate>2017</risdate><volume>69</volume><issue>19</issue><spage>2468</spage><epage>2469</epage><pages>2468-2469</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level <25 mg/dl with the median duration of low LDL level being ~43 weeks.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28494987</pmid><doi>10.1016/j.jacc.2017.02.063</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2017-05, Vol.69 (19), p.2468-2469 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1899106072 |
| source | Elsevier ScienceDirect Journals; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Cardiology Cardiovascular diseases Cholesterol Clinical trials Cognition Cognitive ability Health risks Heart Hypercholesterolemia Incidence Inhibitor drugs Kexin Lipids Low density lipoprotein Patients Populations Protease Protease inhibitors Proteinase Proteinase inhibitors Risk Serine Side effects Subtilisin Therapy |
| title | Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A53%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurocognitive%20Risk%20With%20PCSK9%20Inhibitors:%20Need%20for%20More%20Robust%20Evidence&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Khan,%20Abdur%20Rahman&rft.date=2017-05-16&rft.volume=69&rft.issue=19&rft.spage=2468&rft.epage=2469&rft.pages=2468-2469&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2017.02.063&rft_dat=%3Cproquest_pubme%3E1899106072%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1898070841&rft_id=info:pmid/28494987&rft_els_id=S0735109717361235&rfr_iscdi=true |